Need more information?
Our dedicated team of Novartis representatives based throughout the UK are on hand to answer your local query.
What are you looking for?
top
Image
Image
Cosentyx® (secukinumab): HCP resources
Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years or older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1,2
Full indication for Cosentyx can be found here
Explore our range of educational resources designed for you and your patients
These promotional resources are developed and funded by Novartis UK for healthcare professionals to support their education and the initiation and treatment of patients throughout their Cosentyx journey. Navigate the sections below to find educational resources for download and use by healthcare professionals only, as well as resources that you can share with your patients.
Please do not share links to this page with patients
This section of the website is intended for HCPs only, and contains promotional material. If you wish to direct patients to the patient resources, use the link below.
pro.novartis.com/uk-en/public/medicines/rheumatology/cosentyx/patient-resources
Video
5 mins 56 secs
Video - 15 Jul 2024
5 mins 56 secs
A short video showing you how to prepare and inject Cosentyx with the SensoReady® pen.
Video
6 mins 37 secs
Video - 15 Jul 2024
6 mins 37 secs
A short video showing you how to prepare and inject Cosentyx with the UnoReady® 300mg pen.
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for full product information and administration, including dosing in special populations, before prescribing.1,2 Cosentyx has not been studied in patients with renal impairment or hepatic impairment. No dose recommendations can be made.
Therapeutic Indications1,2
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1,2
AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; ERA; enthesitis-related arthritis; GB, Great Britain; HCP, healthcare professional; HS, hidradenitis suppurativa; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NI, Northern Ireland; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC, Summary of Product Characteristics.
References
Cosentyx® (secukinumab) GB Summary of Product Characteristics.
Cosentyx® (secukinumab) NI Summary of Product Characteristics.
UK | October 2024 | 449383
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
